Immunization, Vaccines and Biologicals

Meningitis Vaccine Project closure conference: ending and new beginnings

22 to 25 February 2016, Addis Ababa, Ethiopia

Introduction

The Meningitis Vaccine Project (MVP) closure conference was organized to celebrate the success of the Project, to recognize all partners for their contributions, to share results and experiences and to plan the next steps to ensure continued support for the remaining vaccination campaigns and a smooth transition into routine immunization programmes. The project, a partnership between WHO and PATH, functioned from 21 June 2001 to 31 December 2014, with a single goal: the development, licensure and introduction of a group A meningococcal conjugate vaccine for use in sub-Saharan Africa.

The conference was unique in convening a wide range of experts, from bench scientists to ministers of health and programme managers, including representatives from all 26 countries in the meningitis belt as well as from all MVP partners, reflecting the unique features of the project itself, whereby integration, inclusiveness and collaboration were the keys to its success.

The conference was jointly hosted by the World Health Organization and PATH. Special thanks to the Bill & Melinda Gates Foundation and the National Philanthropic Trust for their generous financial support.